Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.

Solange Peters,Igor Letovanec,Murielle Mauer,Urania Dafni,Dunson Ejedepang,Wojciech Biernat,Lukas Bubendorf,Arne Warth,Saraswati Pokharel,Niels Reinmuth,Margarita Majem Tarruella,Jose Casas-Martin,Zoi Tsourti,Nesa Marti,Roswitha Kammler,Sarah Danson,Mary O'Brien,Rolf A Stahel

Lung cancer (Amsterdam, Netherlands)（2022）

引用 0|浏览14

暂无评分

摘要

Both cohorts indicate that RANK expression is more common in adenocarcinoma/non-squamous NSCLC and in female patients. No prognostic effect is found, and in the clinical trial involving addition of denosumab to chemotherapy no predictive effect is detected.

查看译文

关键词

Denosumab,NSCLC,RANK,RANKL

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要